Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

60 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Irinotecan-Induced Toxicity: A Pharmacogenetic Study Beyond UGT1A1.
de With M, van Doorn L, Kloet E, van Veggel A, Matic M, de Neijs MJ, Oomen-de Hoop E, van Meerten E, van Schaik RHN, Mathijssen RHJ, Bins S. de With M, et al. Among authors: van meerten e. Clin Pharmacokinet. 2023 Nov;62(11):1589-1597. doi: 10.1007/s40262-023-01279-7. Epub 2023 Sep 16. Clin Pharmacokinet. 2023. PMID: 37715926 Free PMC article.
Effect of omeprazole on the pharmacokinetics and toxicities of irinotecan in cancer patients: a prospective cross-over drug-drug interaction study.
van der Bol JM, Loos WJ, de Jong FA, van Meerten E, Konings IR, Lam MH, de Bruijn P, Wiemer EA, Verweij J, Mathijssen RH. van der Bol JM, et al. Among authors: van meerten e. Eur J Cancer. 2011 Apr;47(6):831-8. doi: 10.1016/j.ejca.2010.11.030. Epub 2011 Jan 6. Eur J Cancer. 2011. PMID: 21216137 Free article. Clinical Trial.
Nivolumab for Squamous-Cell Cancer of Head and Neck.
Bins S, van Meerten E, Mathijssen RH. Bins S, et al. Among authors: van meerten e. N Engl J Med. 2017 Feb 9;376(6):595-6. doi: 10.1056/NEJMc1615565. N Engl J Med. 2017. PMID: 28181785 No abstract available.
Pharmacokinetics of Sublingually Delivered Fentanyl in Head and Neck Cancer Patients Treated with Curatively Aimed Chemo or Bioradiotherapy.
Kuip EJM, Oldenmenger WH, Oomen-de Hoop E, Verduijn GM, Thijs-Visser MF, de Bruijn P, van Meerten E, Koolen SLW, Mathijssen RHJ, van der Rijt CCD. Kuip EJM, et al. Among authors: van meerten e, van der rijt ccd. Cancers (Basel). 2018 Nov 15;10(11):445. doi: 10.3390/cancers10110445. Cancers (Basel). 2018. PMID: 30445772 Free PMC article.
Comparison of toxicity and effectiveness between fixed-dose and body surface area-based dose capecitabine.
de Man FM, Veerman GDM, Oomen-de Hoop E, Deenen MJ, Meulendijks D, Mandigers CMPW, Soesan M, Schellens JHM, van Meerten E, van Gelder T, Mathijssen RHJ. de Man FM, et al. Among authors: van meerten e, van gelder t. Ther Adv Med Oncol. 2019 Apr 15;11:1758835919838964. doi: 10.1177/1758835919838964. eCollection 2019. Ther Adv Med Oncol. 2019. PMID: 31019570 Free PMC article.
Concomitant intraperitoneal and systemic chemotherapy for extensive peritoneal metastases of colorectal origin: protocol of the multicentre, open-label, phase I, dose-escalation INTERACT trial.
de Boer NL, Brandt-Kerkhof ARM, Madsen EVE, Diepeveen M, van Meerten E, van Eerden RAG, de Man FM, Bouamar R, Koolen SLW, de Hingh IHJT, Bakkers C, Rovers KP, Creemers GM, Deenen MJ, Kranenburg OW, Constantinides A, Mathijssen RHJ, Verhoef C, Burger JWA; Dutch Peritoneal Oncology Group (DPOG); Dutch Colorectal Cancer Group (DCCG). de Boer NL, et al. Among authors: van meerten e, van eerden rag. BMJ Open. 2019 Dec 8;9(12):e034508. doi: 10.1136/bmjopen-2019-034508. BMJ Open. 2019. PMID: 31818845 Free PMC article.
Relation between body composition and severe diarrhea in patients treated with preoperative chemoradiation with capecitabine for rectal cancer: a single-centre cohort study.
van Rees JM, Hartman W, Nuyttens JJME, Oomen-de Hoop E, van Vugt JLA, Rothbarth J, Verhoef C, van Meerten E. van Rees JM, et al. Among authors: van meerten e, van vugt jla. BMC Gastroenterol. 2021 Aug 4;21(1):313. doi: 10.1186/s12876-021-01886-3. BMC Gastroenterol. 2021. PMID: 34348673 Free PMC article.
Intraperitoneal Chemotherapy for Unresectable Peritoneal Surface Malignancies.
Guchelaar NAD, Noordman BJ, Koolen SLW, Mostert B, Madsen EVE, Burger JWA, Brandt-Kerkhof ARM, Creemers GJ, de Hingh IHJT, Luyer M, Bins S, van Meerten E, Lagarde SM, Verhoef C, Wijnhoven BPL, Mathijssen RHJ. Guchelaar NAD, et al. Among authors: van meerten e. Drugs. 2023 Feb;83(2):159-180. doi: 10.1007/s40265-022-01828-7. Epub 2023 Jan 12. Drugs. 2023. PMID: 36633826 Free PMC article. Review.
Phase I study of intraperitoneal irinotecan combined with palliative systemic chemotherapy in patients with colorectal peritoneal metastases.
van Eerden RAG, de Boer NL, van Kooten JP, Bakkers C, Dietz MV, Creemers GM, Buijs SM, Bax R, de Man FM, Lurvink RJ, Diepeveen M, Brandt-Kerkhof ARM, van Meerten E, Koolen SLW, de Hingh IHJT, Verhoef C, Mathijssen RHJ, Burger JWA. van Eerden RAG, et al. Among authors: van meerten e. Br J Surg. 2023 Oct 10;110(11):1502-1510. doi: 10.1093/bjs/znad228. Br J Surg. 2023. PMID: 37467389 Clinical Trial.
Intraperitoneal irinotecan with concomitant FOLFOX and bevacizumab for patients with unresectable colorectal peritoneal metastases: protocol of the multicentre, open-label, phase II, INTERACT-II trial.
van de Vlasakker VCJ, Guchelaar NAD, van den Heuvel TBM, Lurvink RJ, van Meerten E, Bax RJF, Creemers GM, van Hellemond IEG, Brandt-Kerkhof ARM, Madsen EVE, Nederend J, Koolen SLW, Nienhuijs SW, Kranenburg O, de Hingh IHJT, Verhoef C, Mathijssen RHJ, Burger JWA; Dutch Peritoneal Oncology Group; Dutch Colorectal Cancer Group. van de Vlasakker VCJ, et al. Among authors: van meerten e. BMJ Open. 2024 Jan 18;14(1):e077667. doi: 10.1136/bmjopen-2023-077667. BMJ Open. 2024. PMID: 38238055 Free PMC article.
60 results